A venture capital firm based in the US has significant experience working with regulatory agencies to gain product approval in both the FDA and CFDA systems. Since its establishment, the firm has invested in over 60 companies and continues to actively pursue life science opportunities with its third fund, targeting 8-10 new investments per year. The firm typically participates in Seed to Series B financing rounds with check sizes between $500K and $2M and will consider companies based in the USA, Europe, and Asia.
The firm takes an opportunistic approach and will evaluate all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, provided the technology is highly disruptive. The firm’s strongest focus and expertise lie in the medical device sector. Within therapeutics, the firm considers pre-clinical and Phase I assets, while in medical devices and diagnostics, it is open to all device classes, including 510(k) and PMA, at both development and clinical trial stages. The firm has invested in companies ranging from those with validated prototypes to those already generating profits prior to investment.
The firm seeks to partner with companies led by experienced management teams, ideally serial entrepreneurs with proven track records. The firm can lead or co-invest but generally prefers to lead rounds in medical device companies and will typically take a board seat in those cases.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment